BNP Paribas Financial Markets Boosts Stock Holdings in scPharmaceuticals Inc. (NASDAQ:SCPH)

BNP Paribas Financial Markets increased its position in shares of scPharmaceuticals Inc. (NASDAQ:SCPH) by 116.9% during the 3rd quarter, Holdings Channel reports. The firm owned 5,753 shares of the company’s stock after purchasing an additional 3,101 shares during the quarter. BNP Paribas Financial Markets’ holdings in scPharmaceuticals were worth $26,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in SCPH. Bank of Montreal Can purchased a new stake in scPharmaceuticals during the second quarter worth about $1,544,000. King Luther Capital Management Corp lifted its position in scPharmaceuticals by 51.8% during the second quarter. King Luther Capital Management Corp now owns 2,205,140 shares of the company’s stock valued at $9,592,000 after purchasing an additional 752,005 shares during the last quarter. Rice Hall James & Associates LLC increased its position in shares of scPharmaceuticals by 76.9% during the 2nd quarter. Rice Hall James & Associates LLC now owns 497,227 shares of the company’s stock valued at $2,163,000 after purchasing an additional 216,122 shares during the last quarter. Assenagon Asset Management S.A. raised its stake in shares of scPharmaceuticals by 266.7% during the second quarter. Assenagon Asset Management S.A. now owns 72,692 shares of the company’s stock worth $316,000 after acquiring an additional 52,870 shares in the last quarter. Finally, AIGH Capital Management LLC boosted its position in scPharmaceuticals by 3.4% during the second quarter. AIGH Capital Management LLC now owns 3,504,365 shares of the company’s stock valued at $15,244,000 after buying an additional 115,206 shares during the period. 89.52% of the stock is owned by institutional investors.

scPharmaceuticals Price Performance

Shares of NASDAQ SCPH opened at $3.39 on Friday. The company has a quick ratio of 6.89, a current ratio of 8.08 and a debt-to-equity ratio of 1.66. scPharmaceuticals Inc. has a twelve month low of $3.08 and a twelve month high of $6.71. The firm has a market cap of $169.64 million, a P/E ratio of -1.78 and a beta of 0.14. The company has a 50 day moving average of $3.81 and a 200 day moving average of $4.34.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on SCPH. Craig Hallum cut their price target on shares of scPharmaceuticals from $16.00 to $12.00 and set a “buy” rating on the stock in a report on Thursday, November 14th. HC Wainwright reaffirmed a “buy” rating and set a $18.00 price objective on shares of scPharmaceuticals in a research report on Thursday, November 14th.

About scPharmaceuticals

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.